Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
在HER2突变的晚期非小细胞肺癌患者的二线/三线治疗中,吡咯替尼与当前标准治疗方案的疗效比较
期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000002453
Mao, Shiqi; Luo, Libo; Yang, Shuo; Wang, Yan; Zhou, Fei; Yu, Jia; Chen, Bin; Gao, Guanghui; Li, Xuefei; Zhao, Chao; Cheng, Lei; Liu, Yiwei; Wang, Wanying; Jia, Keyi; Shao, Chuchu; Liu, Xinyu; Chen, Xiaoxia; Su, Chunxia; Zhou, Caicun; Wu, Fengying; Ren, Shengxiang